• Alligator will shrink its organization to a minimal headcount to oversee HLX22, subject to union negotiations set to start immediately.
• The restructuring follows a decision to halt independent development of mitazalimab, with resources redirected to the out-licensed HLX22 program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.